Drug Profile
Research programme: insulin - Ambrx
Alternative Names: Insulin - AmbrxLatest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx
- Class Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (SC)
- 21 May 2013 Preclinical trials in Diabetes mellitus in USA (SC)